{
    "last_updated": "2025-12-26",
    "data_sources": [
        "ALSCAS WhatsApp Group Discussions (2021-2025)",
        "Target ALS Global Natural History Study",
        "CSIR-IGIB GOMED Program",
        "AIIMS Delhi ALS Initiatives",
        "NIMHANS Bangalore ALS Programs",
        "ProjectMinE Trans-Ancestral Genetics"
    ],
    "overview": {
        "title": "ALS Research Initiatives & Collaborations in India",
        "description": "Comprehensive overview of research collaborations, genetic testing programs, clinical initiatives, and community-driven efforts from ALSCAS WhatsApp group discussions (2021-2025)",
        "key_achievement": "India moving from ZERO ALS research infrastructure to being part of global research community"
    },
    "categories": {
        "genetic_testing_programs": [
            {
                "id": 1,
                "program_name": "CSIR-IGIB Genetic Testing Research Project",
                "status": "Active (2022-Present)",
                "lead_organization": "CSIR-IGIB (Council of Scientific & Industrial Research - Institute of Genomics & Integrative Biology)",
                "lead_researcher": "Dr. Mohammed Faruq, Principal Scientist",
                "program_type": "FREE genetic testing through Government of India's GOMED (Genomics for Rare Disease) program",
                "genes_tested": [
                    "C9orf72 (most common genetic cause - 40% of familial cases)",
                    "SOD1 (20% of familial cases)",
                    "FUS",
                    "TDP43",
                    "OPTN",
                    "VCP",
                    "TBK1"
                ],
                "participants": {
                    "first_batch_2022": "62 PALS registered, 59 completed testing",
                    "november_2025_batch": "39 PALS",
                    "status": "Testing still ongoing",
                    "logistics_support": "ALSCAS covers home collection logistics costs (₹500-1000 per sample)"
                },
                "research_purpose": [
                    "Build India's first ALS genetic database",
                    "Understand genetic patterns specific to Indian population",
                    "Identify candidates for future gene-specific treatments",
                    "Contribute to global ALS genetic research"
                ],
                "how_to_participate": {
                    "step1": "Fill Google Form shared in ALSCAS group",
                    "step2": "Wait for home visit (blood collection scheduled)",
                    "step3": "Give 6ml blood sample",
                    "step4": "Results in ~3 months",
                    "cost": "FREE of cost",
                    "website": "http://gomed.igib.in/genomic-tests"
                },
                "published_research": {
                    "october_2025": "Research study published acknowledging ALSCAS contribution",
                    "presentation": "Data being presented at medical symposiums to attract pharmaceutical companies"
                },
                "what_to_expect": [
                    "Genetic test results identifying specific mutations",
                    "Eligibility for gene-specific treatments (Tofersen for SOD1, future FUS treatments)",
                    "Family genetic counseling",
                    "Contribution to India's ALS research database"
                ],
                "sources": [
                    "http://gomed.igib.in/genomic-tests",
                    "ALSCAS WhatsApp Group - Multiple messages from September 2022 onwards"
                ]
            },
            {
                "id": 2,
                "program_name": "Commercial Genetic Testing Services",
                "status": "Available",
                "providers": [
                    {
                        "name": "Medgenome",
                        "contact": "Dr. Priya Pande, Head - Scientific Affairs",
                        "cost_inr": "17,000-18,000",
                        "coverage": "Pan-India sample collection",
                        "prescription": "Required from neurologist",
                        "limitation": "Does NOT test for C9orf72 (as of September 2022)"
                    },
                    {
                        "name": "Neuberg Diagnostics",
                        "location": "Ahmedabad",
                        "cost_inr": "Similar range"
                    }
                ],
                "genes_tested": "Comprehensive ALS panel including SOD1, FUS, TARDBP, OPTN (Note: Check with provider for latest gene coverage)",
                "turnaround_time": "2-3 weeks",
                "sources": [
                    "ALSCAS WhatsApp Group discussions"
                ]
            }
        ],
        "international_collaborations": [
            {
                "id": 1,
                "collaboration_name": "Target ALS Global Collaboration",
                "status": "Active (December 2024-Present)",
                "organization": "Target ALS, New York USA",
                "ceo_contact": "Dr. Manish Raisinghani",
                "has_detailed_info": true,
                "india_partners": [
                    {
                        "institution": "NIMHANS, Bangalore",
                        "role": "Designated as base for clinical trials"
                    },
                    {
                        "institution": "AIIMS, Delhi",
                        "role": "Designated as base for clinical trials"
                    }
                ],
                "global_natural_history_project": {
                    "description": "Collecting data and biological samples from ALS patients worldwide",
                    "india_contribution": "South Asian population data",
                    "potential_discoveries": [
                        "India-specific genetic factors",
                        "Unique disease progression patterns in South Asian populations",
                        "Younger age of onset patterns",
                        "Slower disease progression in some Indian cases"
                    ]
                },
                "detailed_info": {
                    "about_target_als": "Nonprofit organization focused on accelerating research and drug development for ALS. Connects scientists, clinicians, and pharmaceutical companies worldwide.",
                    "connection_story": "ALSCAS met Dr. Vishnu during an online meeting of International Alliance of ALS/MND Associations, which led to the Target ALS connection.",
                    "meeting_details": {
                        "date": "December 2024",
                        "format": "Connected via Montreal Congress, then online meeting",
                        "participants": "ALSCAS team and Dr. Manish Raisinghani",
                        "facilitator": "Dr. Nirmal Surya facilitated ALSCAS attendance at Montreal and provided continued support"
                    },
                    "global_natural_history_study": {
                        "purpose": "Collect comprehensive data and biological samples from ALS patients worldwide to understand disease patterns and progression",
                        "india_role": "Contributing South Asian population data which may reveal unique genetic and environmental factors",
                        "sample_collection": "Blood, urine, cerebrospinal fluid, and clinical data collection",
                        "expected_outcomes": [
                            "Discovery of India-specific genetic factors",
                            "Understanding younger age of onset in Indian population",
                            "Identifying protective genes in slower-progressing cases",
                            "Positioning India for future clinical trials"
                        ]
                    },
                    "annual_conference": {
                        "date": "May 2025",
                        "format": "Virtual participation for ALSCAS members",
                        "registration": "Registration link shared with community on May 5, 2025",
                        "focus": "Latest advancements in ALS research, drug development updates, clinical trial opportunities"
                    },
                    "significance_for_india": [
                        "First major Target ALS collaboration in India",
                        "NIMHANS already working with Dr. Nalini & Dr. Venugopalan to build data of Indian ALS patients",
                        "AIIMS and NIMHANS designated as clinical trial sites",
                        "Indian patients may access experimental treatments",
                        "Data from Indian population contributes to global understanding",
                        "Our connect with Target ALS was more significant as their main motto is to connect global scientists and teams together"
                    ]
                },
                "montreal_congress": {
                    "event": "International Alliance Congress",
                    "date": "December 2-4, 2024",
                    "location": "Montreal, Canada",
                    "representative": "Raj Kakumani (brother of Vijaya Bharati) represented ALSCAS",
                    "acknowledgment": "Grateful to Dr. Nirmal Surya who made one expensive registration complimentary"
                },
                "events": {
                    "may_2025": "ALSCAS members invited to Target ALS Annual Conference (virtual participation)",
                    "focus": "Latest ALS research developments"
                },
                "what_to_expect": [
                    "India becoming part of global clinical trial network",
                    "Access to international research findings",
                    "Potential for Indian patients to participate in global trials"
                ],
                "sources": [
                    "https://www.targetals.org",
                    "https://targetals.org/global-natural-history-study/",
                    "ALSCAS WhatsApp Group - Messages from December 2024, March 2025, May 2025"
                ]
            },
            {
                "id": 2,
                "collaboration_name": "ProjectMinE - Trans-Ancestral Genetics (TAG)",
                "status": "Active (2022-Present)",
                "meeting_date": "September 30, 2022",
                "lead_organizer": "Dr. Al Khleifat Ahmad, King's College London",
                "participants": [
                    "Dr. Al Khleifat Ahmad (King's College London)",
                    "Dr. Mohammed Faruq (CSIR-IGIB)",
                    "Dr. Gauri Devi (India)",
                    "ALSCAS representatives"
                ],
                "goals": [
                    "Create national database of ALS patients with genetic sequencing",
                    "Present results in medical symposiums",
                    "Attract pharmaceutical and biotech companies to India",
                    "Enable India to participate in global ALS research"
                ],
                "action_items": [
                    "Medical data collection for Indian ALS patients",
                    "Clinical trial opportunities for Indian patients",
                    "National database for pharma company engagement"
                ],
                "sources": [
                    "https://www.projectmine.com",
                    "ALSCAS WhatsApp Group - October 2022 meeting minutes"
                ]
            },
            {
                "id": 3,
                "collaboration_name": "IFNR & IAN - ALS/MND Awareness Recognition",
                "status": "Ongoing (2024-Present)",
                "organization": "Indian Federation of Neurorehabilitation (IFNR) & Indian Academy of Neurology (IAN)",
                "has_detailed_info": true,
                "key_figure": {
                    "name": "Dr. Nirmal Surya",
                    "roles": [
                        "President of IFNR",
                        "Past President of IAN"
                    ],
                    "contribution": "Facilitated recognition of ALS awareness at institutional level"
                },
                "event_details": {
                    "name": "India's First ALS/MND Awareness Day Recognition",
                    "organizers": [
                        "IFNR",
                        "IAN",
                        "ALSCAS"
                    ],
                    "format": "Virtual event",
                    "significance": "Indian Academy of Neurology (IAN) and IFNR recognize importance of ALS awareness day for first time ever in India"
                },
                "speakers": [
                    "Dr. Nirmal Surya (Eminent neurologist, IFNR President)",
                    "Satvinder Kaur (ALSCAS Co-Founder)",
                    "CALS (Caregiver sharing experiences)"
                ],
                "topics_covered": [
                    "Understanding ALS/MND",
                    "Disease management strategies",
                    "Caregiver experiences and insights",
                    "Available support resources in India"
                ],
                "ifnrcon_2025": {
                    "event": "13th Annual IFNR Conference (IFNRCON 2025)",
                    "location": "CMC Ludhiana",
                    "dates": "March 13-16, 2025",
                    "alscas_participation": "Satvinder Kaur invited as panelist for Rehabilitation in ALS session"
                },
                "detailed_info": {
                    "significance": "First ever organized ALS/MND awareness program in India at institutional level",
                    "impact": "Increased awareness among medical community and general public about ALS/MND",
                    "video_recording": "https://www.youtube.com/live/T50GFEOfUfM",
                    "key_takeaways": [
                        "Importance of early diagnosis and intervention",
                        "Multi-disciplinary care approach for ALS patients",
                        "Role of caregivers in disease management",
                        "Available resources and support systems in India"
                    ]
                },
                "sources": [
                    "https://www.youtube.com/live/T50GFEOfUfM",
                    "ALSCAS WhatsApp Group - Event announcements 2024, March 2025"
                ]
            },
            {
                "id": 4,
                "collaboration_name": "International Alliance of ALS/MND Associations",
                "status": "Full Member (July 2024-Present)",
                "organization": "International Alliance of ALS/MND Associations",
                "has_detailed_info": true,
                "membership_details": {
                    "achievement_date": "July 2024",
                    "membership_type": "Full Membership",
                    "organization_name": "ALS Care and Support Foundation India (ALSCAS)",
                    "announcement": "Our ALS care and support foundation just received full membership"
                },
                "detailed_info": {
                    "about_alliance": "Global network of ALS/MND associations working together to support patients, caregivers, and advance research worldwide",
                    "significance_for_india": [
                        "First Indian organization to receive full membership",
                        "Application to join the Alliance as a full member has been approved",
                        "Recognition of ALSCAS's impactful work in India",
                        "Access to global best practices and research",
                        "Platform to showcase Indian ALS community's progress"
                    ],
                    "benefits": [
                        "Networking with global ALS organizations",
                        "Access to international conferences and symposiums",
                        "Knowledge sharing on latest treatments and care protocols",
                        "Collaborative research opportunities"
                    ],
                    "congress_participation": {
                        "event": "International Alliance Congress",
                        "location": "Montreal, Canada",
                        "dates": "December 2-4, 2024",
                        "representative": "Raj Kakumani represented ALSCAS",
                        "significance": "Opportunity to showcase India's ALS research and care initiatives to global medical community",
                        "acknowledgment": "Dr. Nirmal Surya facilitated ALSCAS attendance and provided continued support"
                    }
                },
                "sources": [
                    "https://www.als-mnd.org",
                    "ALSCAS WhatsApp Group - July 2024 announcement, December 2024 congress updates"
                ]
            },
            {
                "id": 5,
                "collaboration_name": "IHBAS - ALS Clinic & Patient Needs Study",
                "status": "In Discussion (2024-Present)",
                "organization": "Institute of Human Behaviour and Allied Sciences (IHBAS), Delhi",
                "director": "Prof. Dr. R.K. Dhamija",
                "has_detailed_info": true,
                "proposed_initiatives": [
                    {
                        "name": "ALS Clinic Establishment",
                        "status": "Proposed",
                        "description": "Dedicated ALS clinic at IHBAS for comprehensive patient care"
                    },
                    {
                        "name": "Patient Needs Assessment Study",
                        "status": "Proposed",
                        "description": "IHBAS can conduct a study on the need assessment of ALS patients"
                    },
                    {
                        "name": "Doctor Training Session",
                        "status": "Requested",
                        "description": "He would like us to conduct a session for the doctors at IHBAS"
                    }
                ],
                "detailed_info": {
                    "meeting_details": {
                        "year": "2024",
                        "participants": "ALSCAS team and Prof. Dr. R.K. Dhamija (Director, IHBAS)",
                        "outcome": "Productive discussions on establishing ALS clinic and conducting patient needs study"
                    },
                    "proposed_als_clinic": {
                        "purpose": "Provide specialized, comprehensive care for ALS patients in Delhi NCR region",
                        "services": [
                            "Diagnosis and treatment",
                            "Multi-disciplinary care coordination",
                            "Physiotherapy and rehabilitation",
                            "Palliative care support"
                        ]
                    },
                    "patient_needs_study": {
                        "objective": "Understand specific challenges, needs, and gaps in care for ALS patients in India",
                        "expected_outcomes": [
                            "Data-driven insights for better care protocols",
                            "Identification of resource gaps",
                            "Policy recommendations for government support"
                        ]
                    },
                    "significance": "Both initiatives are vitally important for improving ALS care infrastructure in India"
                },
                "sources": [
                    "https://ihbas.delhigovt.nic.in",
                    "ALSCAS WhatsApp Group - 2024 meeting updates"
                ]
            },
            {
                "id": 6,
                "collaboration_name": "AKV9 (NU-9) - Global Research Awareness",
                "status": "USA-Only Research (NO India Collaboration)",
                "organization": "AKAVA Therapeutics (USA) & Northwestern University",
                "has_detailed_info": true,
                "important_clarification": "⚠️ IMPORTANT: AKV9 is being developed exclusively in the USA. There is currently NO India-based collaboration for AKV9. This section is included for informational awareness only.",
                "about_akv9": {
                    "original_name": "NU-9 (Northwestern University compound)",
                    "current_name": "AKV9",
                    "developer": "AKAVA Therapeutics (USA), based on Northwestern University research",
                    "lead_researchers": [
                        "Dr. Richard Silverman (Northwestern University)",
                        "Dr. P. Hande Ozdinler (Northwestern University)"
                    ],
                    "note_on_indian_researchers": "Dr. Mukesh Gautam is an Indian researcher AT Northwestern University in USA - he is NOT affiliated with DRDO or any Indian government organization",
                    "type": "Experimental neuroprotective therapy",
                    "target": "Upper motor neuron protection",
                    "unique_aspect": "Aims to protect and potentially reverse upper motor neuron degeneration"
                },
                "research_background": {
                    "preclinical_results": "Showed promising results in genetic ALS mouse models (hSOD1G93A)",
                    "fda_status": "FDA IND (Investigational New Drug) status granted: August 2023",
                    "current_phase": "Phase 1 trials in healthy volunteers (USA-based)",
                    "development_stage": "Early clinical development"
                },
                "india_status": {
                    "current_collaboration": "NONE - No India collaboration exists for AKV9",
                    "india_availability": "NOT available in India",
                    "clinical_trials_in_india": "NONE planned as of December 2025"
                },
                "why_included": "ALSCAS members discussed NU-9 with government officials (DRDO meeting March 2022) as an example of promising global research that India could support. This information helps families understand the global ALS research landscape.",
                "sources": [
                    "Northwestern University press releases",
                    "AKAVA Therapeutics official website",
                    "Scientific Reports publication (peer-reviewed)"
                ]
            }
        ],
        "hospital_initiatives": [
            {
                "id": 1,
                "institution": "AIIMS Delhi",
                "status": "Active (2024-Present)",
                "key_contact": "Dr. Vishnu VY - Associate Professor, In-charge of Neuro-muscular Cell",
                "connection_story": "ALSCAS met Dr. Vishnu during an online meeting of International Alliance of ALS/MND Associations",
                "initiatives": [
                    {
                        "name": "ALS Clinic Establishment",
                        "status": "Under Discussion",
                        "description": "Dr. Vishnu supportive of dedicated ALS clinic at AIIMS",
                        "approach": "Collaborative effort between AIIMS and ALSCAS",
                        "plan": "Multi-disciplinary approach"
                    },
                    {
                        "name": "Public Awareness Programs",
                        "status": "Approved",
                        "description": "ALS awareness programs at AIIMS",
                        "requirement": "Internal approvals across departments"
                    },
                    {
                        "name": "ALS Ready Reckoner",
                        "status": "Under Review",
                        "description": "ALSCAS provided comprehensive ALS guide to AIIMS",
                        "purpose": "Expert review and validation"
                    }
                ],
                "major_event": {
                    "name": "ALS/MND Awareness Day",
                    "date": "June 25, 2025",
                    "venue": "J.L. Auditorium, AIIMS Delhi",
                    "capacity": "500 seats",
                    "chief_guest": "Prof. M. Srinivas (Director, AIIMS)",
                    "participants": [
                        "Prof. M. Srinivas (Director, AIIMS)",
                        "Dr. Vishnu VY and senior neurologists from AIIMS",
                        "HOD and senior doctors of Neurology"
                    ],
                    "format": "Event was live-streamed for wider reach",
                    "outcomes": [
                        "First major institutional collaboration for ALS in India",
                        "Increased awareness among medical community",
                        "Commitment from AIIMS for ongoing support",
                        "Gratitude expressed to Prof. M. Srinivas for unprecedented director-level support"
                    ]
                },
                "additional_engagement": {
                    "race_for_7": "ALSCAS attended Racefor7 event at AIIMS Delhi and got permission to place standee (February 2024)"
                },
                "january_2025_meeting": {
                    "date": "January 2025",
                    "type": "In-person meeting",
                    "note": "Meeting with AIIMS finally getting realised (expected to be in next week) - from January 7, 2025 message"
                },
                "rare_disease_package": {
                    "status": "In Development",
                    "description": "Ministry of Health & Family Welfare (MoHFW) tasked AIIMS to draft funding package for rare diseases without definitive treatment",
                    "alscas_contribution": "Shared economic impact study of ALS with AIIMS"
                },
                "sources": [
                    "ALSCAS WhatsApp Group - Messages from January 2025, June 2025, February 2024"
                ]
            },
            {
                "id": 2,
                "institution": "NIMHANS Bangalore",
                "status": "Active (Ongoing)",
                "key_doctors": [
                    "Dr. Nalini A. (Senior neurologist, ALS specialist)",
                    "Dr. Keerthi Priya (ALS specialist)",
                    "Dr. Deepak Menon (Research trials)"
                ],
                "target_als_collaboration": {
                    "status": "Active",
                    "role": "Working with Dr. Nalini & Dr. Venugopalan to build data of Indian ALS patients"
                },
                "services": [
                    {
                        "name": "Home Visit Program",
                        "cost": "FREE",
                        "description": "Home visiting ALS specialist doctor and team for immobile patients",
                        "target": "Specifically for ALS patients",
                        "awareness": "Many members unaware of this service"
                    },
                    {
                        "name": "Clinical Studies",
                        "trials": [
                            {
                                "name": "Cyclophosphamide Trial",
                                "lead": "Dr. Deepak Menon",
                                "description": "Trials with immunosuppressant"
                            },
                            {
                                "name": "Methylcobalamin Research",
                                "dosage": "25mg injection study",
                                "status": "Phase 2 trials, not yet FDA-approved"
                            }
                        ]
                    },
                    {
                        "name": "Target ALS Collaboration",
                        "role": "Designated as base for clinical trials",
                        "participation": "Part of Global Natural History Study",
                        "activity": "Data collection for international research"
                    },
                    {
                        "name": "Comprehensive ALS Care",
                        "services": [
                            "Multi-disciplinary team approach",
                            "Physiotherapy services",
                            "Palliative care team support"
                        ]
                    }
                ],
                "challenges": [
                    "Not currently participating in trials outside India (as of November 2025)",
                    "Limited clinical trial opportunities"
                ],
                "sources": [
                    "https://www.nimhans.ac.in/neurology/",
                    "ALSCAS WhatsApp Group - Multiple messages 2022-2025"
                ]
            }
        ],
        "government_collaborations": [
            {
                "id": 1,
                "organization": "DRDO (Defence Research & Development Organisation)",
                "status": "Advocacy Meeting (March 2022)",
                "meeting_date": "March 18, 2022",
                "important_clarification": "⚠️ This was a government advocacy meeting to seek guidance on ALS research funding - NOT a research collaboration",
                "meeting_details": {
                    "duration": "45-minute meeting with high-rank DRDO officer",
                    "purpose": "Seeking government guidance for ALS research and drug discovery"
                },
                "discussion_topics": [
                    "How to approach Government for demands on ALS research funding",
                    "Guidance on drug discovery on existing world research (e.g., NU-9) from India perspective",
                    "General inquiry about government support for rare disease research"
                ],
                "outcome": {
                    "guidance_received": "Officer guided ALSCAS on how to approach government for research funding",
                    "note": "This was an advocacy meeting, NOT a DRDO research project or collaboration"
                },
                "sources": [
                    "ALSCAS WhatsApp Group - March 18, 2022 message: 'we three met with high rank DRDO officer for 45 mins today evening.. who listened to us and guided us how to approach Govt for our demands on ALS research and drug discovery on existing world research (e.g. NU-9) from India'"
                ]
            }
        ],
        "treatment_access_initiatives": [
            {
                "id": 1,
                "treatment_name": "Tofersen (Qalsody) Access Initiative",
                "status": "Advocacy Stage",
                "target_mutation": "SOD1-positive patients (~2% of ALS cases)",
                "current_cost": "US$14,230 per dose (~$170,000/year)",
                "india_access": {
                    "current_status": "Not available",
                    "recommendation": "ALSCAS advocating for Indian government/AIIMS/CSIR-IGIB to contact Biogen",
                    "biogen_program": "Biogen Early Access Program",
                    "program_link": "https://www.biogen.com/science-and-innovation/access-programs.html",
                    "requirement": "Major hospital (AIIMS/NIMHANS) must apply to CDSCO"
                },
                "who_needs_it": "Patients who test positive for SOD1 mutation via genetic testing",
                "sources": [
                    "https://www.biogen.com/science-and-innovation/access-programs.html",
                    "ALSCAS WhatsApp Group - Multiple messages 2023-2025"
                ]
            },
            {
                "id": 2,
                "treatment_name": "FUS Mutation Treatment Research",
                "status": "Research Stage in India (2024-2025)",
                "description": "Team in India working on treatment for FUS mutation ALS",
                "target": "Juvenile ALS cases often linked to FUS mutation",
                "current_efforts": [
                    "Reaching doctors and genetic scientists in India",
                    "Goal: Get trial medicine prepared and administered in India",
                    "Looking for more FUS-positive patients for analysis"
                ],
                "clinical_trial_opportunity": {
                    "announcement_date": "February 2025",
                    "source": "Dr. Faruq informed ALSCAS",
                    "seeking": "Patients with SOD1, FUS, or other ALS-associated gene mutations",
                    "contact": "Nitin Kapoor or Satvinder Kaur for participation"
                },
                "who_can_participate": "Patients with confirmed FUS mutation through genetic testing",
                "sources": [
                    "ALSCAS WhatsApp Group - August 2024, February 2025 messages"
                ]
            },
            {
                "id": 3,
                "treatment_name": "Relyvrio (AMX0035) - WITHDRAWN",
                "status": "WITHDRAWN from market",
                "timeline": {
                    "march_2024": "Phase 3 clinical trial failure announced",
                    "january_2025": "Amylyx Pharmaceuticals announced formal intention to remove Relyvrio from market"
                },
                "note": "Relyvrio is no longer being pursued as a treatment option. Families should focus on other available supportive care and emerging treatments.",
                "sources": [
                    "https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrior...",
                    "ALSCAS WhatsApp Group - March 25, 2024: 'Relyvrio has failed its Phase 3 clinical trial and will soon be pulled from the market'",
                    "January 2, 2025 announcement"
                ]
            }
        ],
        "educational_initiatives": [
            {
                "id": 1,
                "initiative_name": "ALS Ready Reckoner",
                "description": "Comprehensive ALS guide created by ALSCAS",
                "distribution": [
                    "Shared with AIIMS for expert review",
                    "Available to all members"
                ],
                "content": "Covers diagnosis, care, management"
            },
            {
                "id": 2,
                "initiative_name": "Newsletter Distribution",
                "recipients": [
                    "AIIMS departments",
                    "NIMHANS",
                    "Fortis hospitals",
                    "Sir Ganga Ram Hospital"
                ],
                "purpose": "Increases awareness among medical professionals"
            },
            {
                "id": 3,
                "initiative_name": "Awareness Events",
                "events": [
                    {
                        "name": "Race for 7 Events",
                        "location": "AIIMS",
                        "frequency": "Multiple years",
                        "note": "ALSCAS attended Racefor7 event at AIIMS Delhi (February 2024)"
                    },
                    {
                        "name": "Global ALS Awareness Day",
                        "date": "June 21",
                        "type": "Annual"
                    },
                    {
                        "name": "MND Day Events",
                        "partners": [
                            "NIMHANS",
                            "Indousrare",
                            "MND Trust"
                        ]
                    }
                ]
            }
        ]
    },
    "timeline": {
        "2021_2022": {
            "title": "Initial Research Connections",
            "events": [
                "Contact established with CSIR-IGIB",
                "First members explore genetic testing options",
                "March 2022: Advocacy meeting with DRDO seeking government guidance for ALS research"
            ]
        },
        "september_2022": {
            "title": "CSIR-IGIB Partnership Launch",
            "subtitle": "Free Genetic Testing Breakthrough",
            "events": [
                "Sohil Parekh shares success story of mother's genetic testing with Dr. Faruq",
                "Dr. Faruq (CSIR-IGIB) offers FREE genetic testing to entire ALSCAS community",
                "62 PALS immediately register for first batch within days",
                "Google Form created for streamlined enrollment",
                "Home blood collection process established (6ml sample required)",
                "Community celebration: First time Indian ALS families get access to comprehensive genetic testing"
            ],
            "community_response": {
                "excitement_level": "Very high - members calling it 'game-changer'",
                "registration_speed": "62 families registered within first week",
                "completed_testing": "59 members actually completed testing",
                "significance": "Previously genetic testing cost ₹17,000-20,000, now FREE through GOMED program",
                "emotional_impact": "Hope for gene-specific treatments like Tofersen (SOD1)"
            },
            "practical_details": {
                "process": "Fill Google Form → Wait for home visit → 6ml blood sample → Results in ~3 months",
                "genes_tested": "C9orf72, SOD1, FUS, TDP43, OPTN, VCP, TBK1",
                "cost_to_families": "₹0 (FREE)",
                "previous_barrier": "₹17k-20k commercial testing was prohibitive for most families"
            }
        },
        "october_2022": {
            "title": "International Collaboration",
            "subtitle": "ProjectMinE Trans-Ancestral Genetics Meeting",
            "events": [
                "Virtual meeting: ProjectMinE-TAG with King's College London",
                "Organized by Dr. Al Khleifat Ahmad of King's College, UK",
                "Participants: Dr. Al Khleifat Ahmad (King's College), Dr. Faruq (CSIR-IGIB), Dr. Gauri Devi, Indian neurologists, ALSCAS team",
                "Discussion: Building India's first national ALS genetic database",
                "Plans announced: Present Indian data at international medical symposiums",
                "Goal defined: Attract pharmaceutical companies to India for clinical trials"
            ],
            "community_significance": {
                "milestone": "First time Indian ALS community represented in global genetic research consortium",
                "patient_hope": "Indian genetic data could reveal unique patterns, enable future trials",
                "discussion_topics": [
                    "Clinical trial opportunities for Indian patients",
                    "National database for pharma company engagement"
                ]
            },
            "whatsapp_reactions": {
                "sentiment": "Cautious optimism - families grateful for global recognition",
                "key_question": "When will Indian patients actually access new treatments?",
                "transparency": "ALSCAS shared full meeting notes with community"
            }
        },
        "november_2022": {
            "title": "Conference Presentation",
            "subtitle": "India's First Large-Scale ALS Genetic Study Revealed",
            "events": [
                "Dr. Faruq presents ALS genetic research findings at National Neurology Conference",
                "Publicly acknowledges ALSCAS collaboration and community contribution",
                "Highlights: India's first large-scale ALS genetic study with 62 registered, 59 completed participants",
                "Data showing genetic patterns in Indian ALS population",
                "Academic recognition of patient advocacy group's role in research"
            ],
            "community_impact": {
                "validation": "ALSCAS work publicly acknowledged by premier research institution",
                "visibility": "ALS community efforts showcased to hundreds of neurologists",
                "credibility_boost": "Enhanced legitimacy for future hospital/government collaborations",
                "member_pride": "Families felt their participation was making scientific difference"
            },
            "research_significance": {
                "first_of_its_kind": "No prior large-scale genetic study on Indian ALS population",
                "data_contribution": "Indian genetic variants now documented in scientific literature",
                "future_implications": "Foundation for understanding ALS in South Asian populations"
            }
        },
        "july_2024": {
            "title": "International Alliance Membership",
            "subtitle": "Full Membership Achieved",
            "events": [
                "ALS Care and Support Foundation India's application to join the Alliance as a full member has been approved",
                "First Indian organization to receive full membership in International Alliance of ALS/MND Associations",
                "Recognition of ALSCAS's impactful work in building India's ALS support community"
            ]
        },
        "december_2024": {
            "title": "Target ALS Connection",
            "subtitle": "India Joins Global Research Network",
            "events": [
                "International Alliance Congress held December 2-4 in Montreal, Canada",
                "Raj Kakumani represented ALSCAS at the congress",
                "ALSCAS team connects with Dr. Manish Raisinghani (CEO, Target ALS)",
                "Follow-up online meeting organized within weeks",
                "Discussion: India's participation in Global Natural History Study",
                "AIIMS Delhi and NIMHANS Bangalore designated as clinical trial sites",
                "Invitation extended: ALSCAS members to attend May 2025 Target ALS Annual Conference (virtual)",
                "Grateful to Dr. Nirmal Surya who made one expensive registration complimentary"
            ],
            "breakthrough_significance": {
                "historic_first": "First time India included in major global ALS research consortium",
                "clinical_trial_potential": "AIIMS & NIMHANS now on map for international drug trials",
                "patient_access": "Indian patients may access experimental treatments through trials",
                "data_value": "Younger onset, slower progression patterns in Indian cases of global interest"
            },
            "community_discussions": {
                "key_questions": [
                    "Will Indian patients qualify for upcoming clinical trials?",
                    "What does 'Natural History Study' mean for my PALS?",
                    "Timeline for actual treatments to reach India?"
                ],
                "hope_indicators": [
                    "India-specific genetic factors might reveal protective genes",
                    "Understanding why some Indian cases progress slower",
                    "Positioning for future breakthrough therapies"
                ]
            }
        },
        "january_2025": {
            "title": "AIIMS Partnership Begins",
            "subtitle": "First Major Institutional Collaboration",
            "events": [
                "In-person meeting: ALSCAS team with Dr. Vishnu VY (Associate Professor, AIIMS Delhi)",
                "Meeting with AIIMS finally getting realised (January 7, 2025)",
                "Dr. Vishnu supportive of dedicated ALS clinic establishment at AIIMS",
                "Discussion: Multi-disciplinary approach covering neurology, pulmonology, nutrition, palliative care",
                "Approval granted: Public ALS awareness programs at AIIMS",
                "ALS Ready Reckoner submitted to AIIMS for expert review and validation",
                "Planning begins: Large-scale awareness event at AIIMS auditorium"
            ],
            "institutional_breakthrough": {
                "significance": "AIIMS is India's premier medical institution - partnership = massive credibility",
                "patient_impact": "Families in Delhi NCR region gain access to specialized ALS care",
                "systemic_change": "AIIMS protocols could become template for other hospitals",
                "advocacy_win": "Patient advocacy group successfully engaging top-tier government hospital"
            },
            "community_reactions": {
                "excitement": "High - AIIMS name carries enormous weight in India",
                "practical_questions": [
                    "When will ALS clinic actually open?",
                    "Will AIIMS train doctors from other cities?",
                    "Can existing patients transfer care to AIIMS?"
                ],
                "gratitude_expressed": "Towards Dr. Vishnu for taking ALS seriously and being supportive"
            }
        },
        "march_2025": {
            "title": "IFNRCON 2025",
            "subtitle": "ALSCAS Representation at National Conference",
            "events": [
                "13th Annual IFNR Conference (IFNRCON 2025) at CMC Ludhiana, March 13-16",
                "Satvinder Kaur (ALSCAS Co-Founder) invited as panelist for Rehabilitation in ALS session"
            ]
        },
        "may_2025": {
            "title": "Target ALS Annual Meeting",
            "subtitle": "Virtual Participation",
            "events": [
                "ALSCAS members received registration link for Target ALS Annual Meet (May 5, 2025)",
                "Virtual participation for Indian ALS community",
                "Focus: Latest advancements in ALS research, drug development updates, clinical trial opportunities"
            ]
        },
        "june_2025": {
            "title": "Historic AIIMS Event",
            "subtitle": "ALS/MND Awareness Day - 500-Person Capacity",
            "events": [
                "Date: June 25, 2025",
                "Venue: J.L. Auditorium, AIIMS Delhi (500-seat capacity)",
                "Chief Guest: Prof. M. Srinivas (Director, AIIMS) - unprecedented director-level support",
                "HOD and senior doctors of Neurology attended",
                "Speakers: Dr. Vishnu VY, senior AIIMS neurologists, ALSCAS representatives",
                "Topics: ALS diagnosis, management, multi-disciplinary care, caregiver support",
                "Live-streamed for nationwide access",
                "Commitment announced: AIIMS ongoing support for ALS clinic and research",
                "We are truly grateful to Prof. M. Srinivas, Director, AIIMS"
            ],
            "unprecedented_achievement": {
                "first_in_india": "Largest institutional ALS awareness event ever organized in India",
                "director_attendance": "AIIMS Director's presence = highest-level institutional backing",
                "doctor_participation": "HOD and senior doctors of Neurology being present = ripple effect across departments",
                "symbolic_importance": "ALS is no longer invisible disease in India's top hospital"
            },
            "community_sentiment": {
                "overwhelmingly_positive": "Families felt seen, heard, validated by medical establishment",
                "tears_of_joy": "Members emotional seeing ALS taken seriously at national level",
                "whatsapp_celebration": "Days of congratulatory messages to ALSCAS team",
                "practical_hope": "Families believing better care and diagnosis now possible"
            },
            "long_term_implications": {
                "training_hub": "AIIMS could train neurologists from other Indian hospitals",
                "research_pipeline": "Patient needs assessment study and rare disease funding package discussions",
                "government_attention": "Ministry of Health now aware of ALS burden in India"
            }
        },
        "october_2025": {
            "title": "Research Publication",
            "subtitle": "First Major Genetic Study on Indian ALS Population",
            "events": [
                "CSIR-IGIB publishes research study in peer-reviewed journal",
                "Paper explicitly acknowledges ALSCAS participation and contribution",
                "Data from 62 registered, 59 completed Indian ALS patients now in scientific literature",
                "Genetic patterns specific to Indian/South Asian population documented",
                "Presentation of findings at medical symposiums to attract pharmaceutical interest",
                "First time Indian ALS genetic data available for global research community"
            ],
            "scientific_milestone": {
                "legitimacy": "Patient advocacy group's efforts result in peer-reviewed publication",
                "data_legacy": "Indian ALS genetic data now permanently part of global knowledge",
                "pharma_attention": "Published data attracts biotech/pharmaceutical company interest",
                "research_continuation": "Opens door for follow-up studies and expanded research"
            },
            "patient_impact": {
                "immediate": "Families who tested positive for SOD1/FUS now eligible for gene-specific treatments",
                "future": "Indian genetic database enables faster enrollment in future trials",
                "pride": "Patients proud their participation contributed to science",
                "hope": "Published data may attract clinical trials to India"
            },
            "community_acknowledgment": {
                "gratitude_to_dr_faruq": "Members thanking Dr. Faruq for keeping promise to publish with ALSCAS acknowledgment",
                "validation": "Proof that patient participation in research creates real scientific value",
                "momentum": "Success energizes community for future research collaborations"
            }
        },
        "november_2025": {
            "title": "Genetic Testing Expansion",
            "subtitle": "Second Batch - Streamlined Process",
            "events": [
                "39 new PALS enrolled for genetic testing (second batch)",
                "First list of 39 PALS sent in first batch (November 19, 2025)",
                "Streamlined home collection process based on first batch learnings",
                "ALSCAS now covering home collection logistics costs (₹500-1000 per sample)",
                "Faster enrollment: Google Form refined, approval within days",
                "Results expected: February 2026 (3-month processing time)",
                "Families from multiple cities: Delhi, Mumbai, Bangalore, Chennai, Pune, Kolkata"
            ],
            "process_improvements": {
                "from_first_batch": [
                    "Home collection scheduling now smoother",
                    "Clear communication about 6ml blood sample requirement",
                    "Family genetic counseling information provided upfront",
                    "Expectation setting: Results timeline, what test covers, implications"
                ],
                "alscas_support_increased": "Covering collection costs removes financial barrier for families",
                "doctor_involvement": "Some neurologists now proactively recommending CSIR-IGIB testing to patients"
            },
            "community_maturity": {
                "informed_participation": "Families now understand gene-specific treatments (Tofersen for SOD1, future FUS treatments)",
                "realistic_expectations": "Understanding that positive result = eligibility, not guaranteed access",
                "peer_support": "First batch families guiding second batch through process",
                "database_building": "Growing Indian ALS genetic database = stronger pharma negotiation position"
            },
            "clinical_trial_announcement": {
                "february_2025_update": "Dr. Faruq informed community of potential clinical trial in India",
                "target_mutations": "SOD1, FUS, and other ALS-associated genes",
                "significance": "Would be India's FIRST ALS clinical trial if materialized",
                "contact_points": "Nitin Kapoor, Satvinder Kaur coordinating interested patient enrollment"
            }
        }
    },
    "key_contacts": {
        "research_collaborators": [
            {
                "name": "Dr. Mohammed Faruq",
                "position": "Principal Scientist, CSIR-IGIB",
                "focus": "ALS genetic testing, GOMED program",
                "contact": "Via http://gomed.igib.in"
            },
            {
                "name": "Dr. Vishnu VY",
                "position": "Associate Professor, AIIMS Delhi",
                "focus": "Neuromuscular diseases, ALS clinic development",
                "contact": "Through AIIMS Neurology Department"
            },
            {
                "name": "Dr. Manish Raisinghani",
                "position": "CEO, Target ALS (New York)",
                "focus": "Global ALS research coordination",
                "partnership": "AIIMS, NIMHANS collaboration"
            },
            {
                "name": "Dr. Nalini A.",
                "position": "Senior Neurologist, NIMHANS Bangalore",
                "focus": "ALS specialist, clinical care",
                "contact": "Through NIMHANS Neurology OPD"
            },
            {
                "name": "Dr. Keerthi Priya",
                "position": "ALS Specialist, NIMHANS",
                "focus": "Clinical trials, patient care",
                "contact": "Through NIMHANS"
            },
            {
                "name": "Dr. Nirmal Surya",
                "position": "President, IFNR; Past President, IAN",
                "focus": "Medical community engagement, ALS awareness facilitation",
                "contribution": "Facilitated ALSCAS attendance at international events"
            },
            {
                "name": "Dr. Al Khleifat Ahmad",
                "position": "Researcher, King's College London",
                "focus": "ProjectMinE Trans-Ancestral Genetics",
                "contact": "Via ProjectMinE"
            }
        ],
        "testing_services": [
            {
                "name": "Medgenome",
                "contact": "Dr. Priya Pande, Head - Scientific Affairs",
                "service": "Commercial genetic testing",
                "cost_inr": "17,000-18,000",
                "coverage": "Pan-India sample collection",
                "limitation": "Does NOT test for C9orf72 (as of September 2022)"
            },
            {
                "name": "CSIR-IGIB GOMED",
                "service": "Free research-based genetic testing",
                "website": "http://gomed.igib.in/genomic-tests",
                "enrollment": "Through ALSCAS Google Form"
            }
        ],
        "organizations": [
            {
                "name": "Target ALS",
                "website": "https://www.targetals.org",
                "focus": "Global research coordination",
                "annual_conference": "May each year"
            },
            {
                "name": "ProjectMinE",
                "focus": "Global genetic research",
                "partners": "King's College London, CSIR-IGIB"
            },
            {
                "name": "Biogen",
                "drug": "Tofersen (Qalsody)",
                "early_access": "https://www.biogen.com/science-and-innovation/access-programs.html"
            },
            {
                "name": "ALSCAS (ALS Care and Support Foundation)",
                "website": "Contact via WhatsApp group",
                "social_media": {
                    "linkedin": "https://www.linkedin.com/company/als-care-and-support-foundation",
                    "instagram": "https://www.instagram.com/alscasindia",
                    "twitter": "https://twitter.com/alscasindia"
                },
                "focus": "Patient support, advocacy, research collaboration in India"
            }
        ],
        "social_media_links": {
            "alscas_linkedin": "https://www.linkedin.com/company/als-care-and-support-foundation",
            "alscas_instagram": "https://www.instagram.com/alscasindia",
            "alscas_twitter": "https://twitter.com/alscasindia",
            "note": "Follow ALSCAS on social media for latest updates on research initiatives, events, and support resources"
        }
    },
    "success_stories": [
        {
            "achievement": "750+ Families Supported",
            "description": "From small discussion group to major support network. Terms like 'ALS' and 'MND' now recognized."
        },
        {
            "achievement": "First ALS Genetic Study in India",
            "description": "62 registered, 59 completed patients in initial batch. Published research acknowledging ALSCAS. Building national genetic database."
        },
        {
            "achievement": "AIIMS Partnership",
            "description": "First institutional collaboration. Historic awareness event (June 25, 2025). Commitment for ALS clinic. Director-level support from Prof. M. Srinivas."
        },
        {
            "achievement": "Global Recognition",
            "description": "Target ALS partnership. ProjectMinE collaboration. International Alliance for ALS/MND full membership (July 2024). Featured in global ALS community."
        },
        {
            "achievement": "Government Engagement",
            "description": "AIIMS tasked to draft rare disease funding package. ALSCAS input included. Economic impact study submitted."
        },
        {
            "achievement": "Research Publication",
            "description": "October 2025: First major study published. Indian ALS genetic data now in scientific literature. ALSCAS acknowledged as contributor."
        }
    ],
    "what_to_expect": {
        "immediate_1_2_years": [
            {
                "expectation": "ALS Clinic at AIIMS Delhi",
                "status": "Under discussion",
                "description": "Multi-disciplinary care, standardized treatment protocols, training hub for other hospitals"
            },
            {
                "expectation": "Genetic Testing Results",
                "timeline": "November 2025 batch results expected by February 2026",
                "benefits": "Access to gene-specific treatments if positive, family genetic counseling"
            },
            {
                "expectation": "Clinical Trial in India",
                "status": "Dr. Faruq mentioned potential trial (February 2025)",
                "target": "Possibly for FUS, SOD1, or other ALS-associated gene mutations",
                "significance": "Would be first ALS clinical trial in India"
            },
            {
                "expectation": "Expanded Access to Tofersen",
                "target": "SOD1-positive patients",
                "mechanism": "Through Biogen early access program",
                "requirement": "AIIMS/NIMHANS application to CDSCO"
            }
        ],
        "medium_term_2_5_years": [
            {
                "expectation": "India as Clinical Trial Hub",
                "description": "AIIMS and NIMHANS as designated sites. Target ALS partnership bearing fruit. Access to global drug trials. Indian patients eligible for experimental treatments."
            },
            {
                "expectation": "National ALS Registry",
                "description": "Comprehensive database of all Indian ALS patients. Genetic data integrated. Disease progression tracking. Research resource for drug companies."
            },
            {
                "expectation": "More Treatment Options",
                "description": "SPG302 trials in India. New gene-specific therapies. Combination treatments. Symptomatic management drugs."
            },
            {
                "expectation": "Insurance Coverage",
                "description": "Government recognition of ALS as covered condition. Private insurance including genetic disorders. Financial support for equipment/care."
            }
        ],
        "long_term_5_10_years": [
            {
                "expectation": "India-Specific Research",
                "description": "Discovery of South Asian genetic factors. Understanding younger age of onset in India. Protective genes in slower-progressing cases. Environmental factors unique to India."
            },
            {
                "expectation": "Gene Therapy in India",
                "description": "CRISPR-based treatments. Gene silencing therapies (like Tofersen but for more genes). Indigenous development of gene therapies. Affordable access through government programs."
            },
            {
                "expectation": "Network of ALS Clinics",
                "description": "Following UK model (20+ MND centers). Major cities: Delhi, Mumbai, Bangalore, Chennai, Kolkata. Standardized care protocols. Telemedicine connections."
            },
            {
                "expectation": "Cure/Disease Modification",
                "description": "Treatments that stop progression. Reversal of symptoms. Prevention for familial cases. Precision medicine based on genetic profile."
            }
        ]
    },
    "important_notes": {
        "current_limitations": [
            "No active clinical trials in India (NIMHANS confirmed not participating in outside trials - Nov 2025)",
            "AIIMS not yet running ALS-specific trials",
            "No infrastructure for trial management",
            "Treatment access barriers - most experimental drugs not available in India"
        ],
        "realistic_expectations": [
            "Genetic testing will provide results and contribute to research",
            "May get peace of mind if negative for mutations",
            "Even if positive, treatment may not be available/affordable immediately",
            "Results take 3 months",
            "Clinical trials 2-3 years away minimum with strict eligibility criteria"
        ],
        "what_was_corrected": {
            "note": "This data was verified against ALSCAS WhatsApp chat records (2021-2025) in December 2025",
            "corrections_made": [
                "AKV9/NU-9: Clarified this is USA-only research with NO India collaboration; Dr. Mukesh Gautam is at Northwestern University, NOT DRDO",
                "DRDO meeting: Reframed as advocacy meeting for government guidance, NOT a research collaboration",
                "First genetic testing batch: Corrected to 62 registered, 59 completed",
                "Satvinder Kaur: Correctly identified as ALSCAS Co-Founder",
                "Relyvrio: Updated timeline - Phase 3 failure March 2024, withdrawal announced January 2025",
                "Medgenome contact: Updated to Dr. Priya Pande; noted C9orf72 limitation",
                "Added: Dr. Al Khleifat Ahmad as ProjectMinE organizer",
                "Added: Raj Kakumani as Montreal Congress representative",
                "Added: Race for 7 event at AIIMS (February 2024)",
                "Added: IFNRCON 2025 participation details"
            ]
        },
        "bottom_line": "India's ALS community is building the foundation for future breakthroughs, one patient, one test, one collaboration at a time. Cure not imminent (5-10 year horizon more realistic). Current focus: Understanding disease, preparing for trials. Participation in research helps future generations even if not current patients."
    }
}